MannKind Corporation (NASDAQ:MNKD) New Labeling Accepted By FDA


Traders News Source has released a comprehensive report on MannKind Corporation (NASDAQ:MNKD), a biopharma entity concentrating its efforts on the discovery and development of distinct therapeutic offerings for ailments such as diabetes. The firm’s only approved offering, Afrezza is a rapid-acting inhaled insulin. It is used to regulate high blood sugar in people with type 1 and type 2 diabetes.

The details

Afrezza obtained regulatory approval from the U.S. FDA in June 2014, and has been accessible by prescription in the U.S. since February 2015. The drug relies on MannKind’s Technosphere technology, a proprietary drug delivery platform that enables for the oral inhalation for numerous therapeutics. The Traders News Source last coverage of company, published September 5, 2017, highlighted Afrezza sales after the cancelation of the Sanofi agreement, the firm’s cash reserves and burn rate. Since that report, the shares have jumped over 184% and there are multiple catalysts that cannot be ignored.

Afrezza is used to enhance glycemic control in adult people with diabetes. The product comprises of a dry powder formulation of insulin (human) that is offered by a small portable inhaler. Administered at the start of a meal, Afrezza dissolves fast upon inhalation to the lung and provides insulin fast to the bloodstream, hitting peak insulin levels within just 12 to 15 minutes of administration.

MannKind management expects that its proprietary Technosphere know-how is a candidate for delivery of several drug compounds. The firm is also looking past Afrezza with several other prospective drugs in its pipeline.

In the last trading session, the stock price of MannKind jumped more than 2% to close the day at $5.42. The gains came at a share volume of 10.12 million compared to average share volume of 11.48 million. After the recent gains, the market cap of firm was noted at around $622 million.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.